Welcome to our dedicated page for BlackRock Health Sciences Term Trust SEC filings (Ticker: BMEZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BlackRock Health Sciences Term Trust (BMEZ) SEC filings page on Stock Titan is intended to help investors review the regulatory documents and formal communications associated with this NYSE‑listed closed-end management investment company. While recent press releases emphasize that annual and semi‑annual reports and other regulatory filings for the fund are accessible on the U.S. Securities and Exchange Commission (SEC) website, this page aggregates those filings and pairs them with AI‑assisted analysis.
According to the Polygon description, BMEZ’s stated investment objective is to provide total return through a combination of current income and long‑term capital appreciation, with a strategy that, under normal market conditions, involves investing at least 80% of total assets in equity securities of energy and natural resources companies and equity derivatives with exposure to that industry. In the fund’s SEC reports, investors can expect to see discussions of how the portfolio and results relate to this objective, along with details on distribution practices and managed distribution plans that are described in BlackRock’s press materials.
Although no specific BMEZ filings are listed in the provided data, BlackRock’s communications note that key documents are filed with the SEC, including tender offer statements on Schedule TO for share repurchase programs, and periodic shareholder reports. On Stock Titan, these filings are presented with AI‑powered summaries designed to explain the main points of lengthy documents, highlight changes in distribution policies, and clarify the structure and terms of tender offers or other corporate actions.
Users can use this page to quickly locate BMEZ regulatory materials such as tender offer documentation and periodic reports as they become available from EDGAR. The AI layer aims to make complex language more accessible, while the underlying filings remain the primary source for detailed, legally binding information about BlackRock Health Sciences Term Trust.
Liu Xiang, a portfolio manager for BlackRock Health Sciences Term Trust, reported multiple equity-related transactions dated January 30, 2026. The filing shows the exercise of derivative awards into 777.9221 shares of common stock, followed by a same-day sale of those 777.9221 shares at $15.21 per share, leaving no directly held common stock.
The transactions also include an award of 1,026.693 phantom shares at a reference value of $15.21. Each phantom share is the economic equivalent of one share of common stock and is payable in cash, vesting in equal installments on each of the first three anniversaries of the award.
BlackRock Health Sciences Term Trust (BMEZ) portfolio manager Erin H. Xie reported a mix of phantom share awards, exercises, and a stock sale on January 30, 2026. Xie was granted 17,560.4931 phantom shares, each economically equivalent to one common share and payable in cash subject to vesting.
On the same date, Xie exercised previously granted phantom shares into 25,676.2744 common shares, then disposed of all 25,676.2744 common shares in a sale at $15.21 per share, leaving no directly owned common stock after the transactions. The phantom share awards vest in equal installments over three years.
BlackRock Health Sciences Term Trust director reports share sales in Form 4 filing. The director sold 10,294 common shares of BMEZ on 12/18/2025 at a price of $14.98 per share, followed by a sale of 0.422 share on 12/19/2025 at $14.96 per share. After these direct transactions, the director no longer held the shares directly. The filing also reports corresponding transactions in common stock held indirectly by the director's spouse on the same dates and prices, with those indirect holdings also reduced to zero. The report is filed for one reporting person, who serves as a director of the trust, and is signed by an attorney-in-fact.